SCHEMBL5658337

SCHEMBL5658337

CCS(=O)(=O)N1CCN(c2ccc(C(=O)NCc3ccc(NC4=NCCN4)cc3)cc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRA2A P08913 5/20 0.55
ADRA2B P18089 5/20 0.55
ADRA2C P18825 5/20 0.55
JAK2 O60674 3/20 0.46
JAK1 P23458 2/20 0.46
JAK3 P52333 2/20 0.46
HDAC1 Q13547 3/20 0.45
KDM1A O60341 2/20 0.45
MLLT1 Q03111 1/20 0.44
PTGIR P43119 2/20 0.43
KMT2A Q03164 2/20 0.43
SMN1; SMN2 Q16637 3/20 0.42
MEN1 O00255 1/20 0.42
CYP2C19 P33261 1/20 0.42
HTT P42858 1/20 0.42
NPSR1 Q6W5P4 1/20 0.42
ACE2 Q9BYF1 1/20 0.41
LMNA P02545 1/20 0.41
MAPT P10636 1/20 0.41
NAMPT P43490 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5657476 0.95 ADRA2A (0.51) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5657361 0.93 ADRA2A (0.55) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5657469 0.90 ADRA2A (0.52) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5659486 0.89 ADRA2A (0.57) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5658814 0.89 ADRA2A (0.59) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5660187 0.89 ALDH1A1 (0.52) ADRA2AADRA2BADRA2CKMT2AMEN1
SCHEMBL5658117 0.88 ADRA2A (0.59) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5656488 0.87 ADRA2A (0.58) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5659076 0.87 ADRA2A (0.58) ADRA2AADRA2BADRA2CJAK2JAK1
SCHEMBL5654958 0.86 ADRA2A (0.57) ADRA2AADRA2BADRA2CJAK2JAK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-7279498-B2 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC (US) 2007-10-09 US disclosed
US-6998414-B2 Substituted arylamides as IP antagonists ROCHE PALO ALTO LLC (US) 2006-02-14 US disclosed
US-20060004075-A1 Substituted aryl amides as IP antagonists ROCHE PALO ALTO LLC 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004075-A1 Substituted aryl amides as IP antagonists INSR, INSRR, GIPR ADRA2A 90/4885ADRA2B 82/4885ADRA2C 112/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.